Mike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. This trade represents a 1.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25.

Beta Bionics Stock Up 2.1%

Shares of NASDAQ:BBNX opened at $21.89 on Friday. The company’s fifty day moving average is $17.66 and its two-hundred day moving average is $14.05. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The company has a market cap of $984.83 million, a P/E ratio of -13.27 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities research analysts anticipate that Beta Bionics, Inc. will post -2.06 earnings per share for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently made changes to their positions in the company. Eventide Asset Management LLC raised its position in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after acquiring an additional 37,476 shares in the last quarter. BlackRock Inc. bought a new stake in Beta Bionics in the second quarter worth approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Beta Bionics during the 4th quarter worth $40,437,000. Eversept Partners LP acquired a new position in shares of Beta Bionics during the 4th quarter worth $20,667,000. Finally, 12 West Capital Management LP bought a new position in shares of Beta Bionics during the 4th quarter valued at $17,520,000.

Wall Street Analyst Weigh In

BBNX has been the topic of several research analyst reports. Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners increased their price target on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday. William Blair started coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Bank of America increased their target price on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Robert W. Baird lifted their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $21.90.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.